Clinical Trial Detail

NCT ID NCT01870505
Title BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center.
Indications

breast cancer

Therapies

Alpelisib + Exemestane

Alpelisib + Letrozole

Age Groups: senior adult

No variant requirements are available.